D espite worldwide increases in the prevalence of chronic liver disease due to viral hepatitis and nonalcoholic steatohepatitis (NASH), patients with cirrhosis are living longer with more advanced disease because of improved medical and surgical management. 1 As a result, they are at risk for other diseases and morbidities that patients with cirrhosis might not have experienced in past decades. Patients with cirrhosis now have a significant lifetime risk of hepatocellular carcinoma (HCC) and obesity-related diseases, and they may require emergent or elective surgical procedures other than liver transplantation. Early reports of outcomes of standard surgical procedures in patients with cirrhosis described intolerable mortality rates as high as 67%. 2 Improved management and better selection of patients with cirrhosis have led to improved surgical survival and the development of new risk prediction algorithms. Nevertheless, the evaluation and treatment of the patient with cirrhosis in whom an invasive surgical procedure is planned is not standardized, and there are no definitive prospective trials to provide clarity to clinicians in assessing patients in the preoperative period and managing them in the postoperative period. The modern literature on surgical risk stratification in cirrhosis patients consists of case reports, small series, and only a few serious attempts to stratify risk. This review summarizes the available data and recommendations based on expert opinion on how best to predict surgical outcomes and optimize the condition of patients with cirrhosis who undergo surgical procedures. Table 1 summarizes our recommendations.
Unique Pathophysiologic Risks in the Patient With Cirrhosis
The pathophysiology of chronic liver disease and portal hypertension predisposes the patient with cirrhosis to complications related to surgical procedures. A comprehensive review of this pathophysiology is beyond the scope of this article, 3, 4 but several points warrant emphasis. The patient with cirrhosis generally has protein synthetic dysfunction that progresses as the liver disease advances and results in the malnutrition/ sarcopenia syndrome, which hinders wound healing and physical recovery from a surgical procedure. Portal hypertension also progresses with advancing cirrhosis, thereby raising the risk of surgical bleeding complications involving the collateral circulation, especially in the splanchnic system in the thoracic and peritoneal cavities. Splenic sequestration, in addition to a possible contribution from thrombopoietin deficiency, 5 leads to peripheral thrombocytopenia, which can interfere with primary hemostasis. Disruptions in secondary hemostasis (coagulation) and fibrinolysis can lead to a propensity to either bleeding or clotting, and the net effect can be difficult to predict on the basis of traditional laboratory testing. 4 Current systems of deceased donor organ allocation in the United States 6 result in the selection of liver transplant recipients who are likely to have renal dysfunction, which complicates fluid management and leads to reduced renal excretion of drugs; hepatic protein synthetic dysfunction may also impair hepatic drug metabolism. The result is a change in the pharmacokinetic handling of medications. All of these pathophysiologic alterations lead to a significant potential for morbidity and mortality related to surgery. Primary hepatic resection, usually for malignancy, is particularly hazardous in this population. It can acutely exacerbate all of the aforementioned pathophysiologic changes due to a further reduction in liver mass, and may thereby Patients should be referred to a surgical team with experience in the care of patients with cirrhosis and portal hypertension whenever possible. Patients with Child-Pugh class C (CTP score >10) or a MELD score >20 pose a high risk of postoperative decompensation and death. Avoid or delay until after liver transplantation, if possible, all but the most urgent and life-saving procedures in this population. BPA 5: TIPS is not routinely recommended before surgical procedures in patients with cirrhosis and portal hypertension with abdominal collaterals. Small uncontrolled case series have demonstrated the ability to decompress collateral vessels with TIPS preoperatively in patients requiring deep pelvic and colonic resections; however, the absolute benefit of TIPS over conservative management is not established. BPA 6: The special case of primary liver resection in a patient with cirrhosis, usually for malignancy, has been studied more thoroughly than other general surgical procedures. Data support the safety profile of segmental liver resections in patients without clinically significant portal hypertension, as indicated by an HVPG <10 mm Hg. A validated surrogate measure of lack of clinically significant portal hypertension is the absence of venous abdominal collaterals on imaging or of esophageal varices on endoscopy, peripheral blood platelet count >100,000/mL, or hepatic transient elastography values of <23kPa. BPA 7: There are no established preoperative safety thresholds for common laboratory values related to bleeding and clotting. The INR is not predictive of procedural bleeding risk in patients with cirrhosis. We do not recommend protocol transfusions to a target INR in patients with cirrhosis. In vitro studies suggest that a platelet count >50,000/mL is adequate to generate thrombin and provide stable clot formation and retrospective clinical studies show an increased bleeding tendency in patients with a platelet count lower than this threshold. The literature provides no evidence to support protocol transfusions, but critically ill patients with plasma fibrinogen levels <100 mg/dL have more bleeding events.
Handle coagulation management on a case-by-case basis preferably using viscoelastic testing directed therapy and avoid needless transfusions or volume overload. BPA 8: Involve a skilled medical team with experience in treating patients with cirrhosis in the postoperative management of patients with cirrhosis, and obtain early consultation to help avoid progressive complications. Achieve optimal control of ascites, variceal bleeding risk, and hepatic encephalopathy before surgery, if possible. Monitor renal and hepatic function at least daily in the postoperative period.
increase the postoperative risk of rapidly progressive hepatic failure.
Predicting Surgical Risk in a Patient With Cirrhosis
Surgical procedures are classified broadly as those that are lifesaving, such as cardiovascular or cancer surgery and emergency interventions, and those that are carried out to improve a patient's quality of life. The challenge for the care team is to assess the surgical risks before deciding whether the procedure can be carried out safely, should be delayed until the patient has undergone liver transplantation, or is best avoided completely, especially in the high risk patient who may not be a liver transplant candidate. Surgical and consultative teams must also consider the idea of futility in their decision-making process. 7 If the surgical risk is much higher than the chance of a good outcome from the perspective of the patient, then the procedure should be considered futile and avoided regardless of the patient's degree of liver disease. For example, Teh et al 8 showed that cirrhotic patients undergoing surgery categorized preoperatively as American Society of Anesthesiologists (ASA) class V (see below) had a median survival of 2 days, a 90% mortality rate at 14 days, and a 100% mortality rate at 90 days. The risk of postoperative mortality and complications is related to the degree of hepatic dysfunction, comorbidities, type of surgical procedure, and expertise of the management team. Of these factors, the severity of the liver disease appears to be the most important factor in determining mortality risk. The severity of liver disease has traditionally been assessed in the literature by the Child-Turcotte-Pugh (CTP) score (ChildPugh class) 9 and the Model for End-Stage Liver Disease (MELD) score. Table 2 summarizes the components of the various severity scales that are used in practice. Do not use NSAIDs because they can impair renal blood flow. Patients with cirrhosis, especially those with heavy alcohol use, can be susceptible to acetaminophen toxicity at doses lower than those that may cause toxicity in the general population. Do not prescribe combination opiate/acetaminophen pain relievers to take home after surgery because the patient may be unaware of the presence of acetaminophen in various over-the-counter products and unintentional acetaminophen overdose and hepatotoxicity can result. BPA 12: The gallbladder wall may appear thickened on imaging, which may lead to the erroneous diagnosis of acute cholecystitis. A diagnosis of acute cholecystitis should be made only in the appropriate clinical setting, usually in the presence of biliary pain. There is a significant risk of complications after cholecystectomy in patients with cirrhosis. Avoid elective cholecystectomy in a patient with confirmed cirrhosis. Refer patients who require cholecystectomy to a surgical team with experience in invasive procedures in the cirrhotic population. BPA 13: Except for incarceration that cannot be manually reduced or suspected strangulation with bowel ischemia or gangrene, abdominal hernia surgery should be avoided in the patient with cirrhosis and ascites unless the ascites is completely controlled. Wound dehiscence, peritonitis, and poor outcomes frequently occur when ascites recurs after hernia surgery. BPA 14: Patients who experience hepatic decompensation after surgery may become candidates for liver transplantation. The MELD score cutoff value for selecting patients for a liver transplant evaluation before elective surgery is not clear. We recommend preoperative liver transplant evaluation when the predicted postoperative 3-month mortality rate is greater than 15% as reflected by surgical risk stratification models or when the MELD score is !15. BPA 15: Centers with expertise in surgery in cirrhotic patients may perform bariatric surgery in this population but clinically significant portal hypertension is a contraindication to the operation. In highly selected patients with obesity and decompensated cirrhosis undergoing liver transplantation, a sleeve gastrectomy at the same time as liver transplantation is an option.
ASA, American Society of Anesthesiologists; BPA, best practice advice; CTP, Child-Turcotte-Pugh; HVPG, hepatic vein pressure gradient; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; NSAID, nonsteroidal anti-inflammatory drug; TIPS, transjugular intrahepatic portosystemic shunt.
CTP Score and ASA Physical Status Classification
Historically, the CTP score has been used to stage the degree of liver dysfunction and severity of portal hypertension in patients with cirrhosis and this system has largely withstood the test of time. Pre-MELD score era studies showed a good correlation between the ChildPugh class (combined with other variables) and surgical mortality. 10 In general, patients with Child-Pugh class A cirrhosis may undergo surgery in the absence of thrombocytopenia or clinically significant portal hypertension; only selected patients with Child-Pugh class B cirrhosis are elective surgical candidates; and patients with Child-Pugh class C cirrhosis are not considered candidates for elective surgery. Recent analyses, however, show less of a correlation between the Child-Pugh class and surgical outcomes, likely because of low numbers of patients with Child-Pugh class C cirrhosis included in modern series, in part due to avoidance of surgery in patients with decompensated cirrhosis. 11 Nevertheless, the presence of ascites (a component of the CTP score but not the MELD score), especially massive ascites, correlates with poor surgical outcomes in many analyses. Because of the somewhat subjective nature of estimating the severity of ascites and encephalopathy, use of the CTP score for surgical risk stratification has been largely supplanted by the MELD score, which encompasses the objective liver functiondependent components of the CTP score that have been found to be predictive of outcomes (see below). 12 The MELD score is less effective in describing the occasional patient with severe portal hypertension but preserved hepatic synthetic function; in these patients, the CTP score may be a more useful tool.
The ASA physical classification system has been used in some form since the early 1940s as a gross measure of the risk of administering anesthesia for surgical procedures. 13 The system classifies patients into illness levels that correlate roughly with surgical outcomes in some circumstances, but the ASA score is generally thought of as a measure of comorbidity or disease severity rather than a direct predictor of outcome, particularly in patients with cirrhosis.
14 The classification system also suffers from poor interobserver variability and is somewhat subjective. Moreover, there is no category for moderate disease, only for mild and severe disease. Despite these weaknesses, the ASA classification is still used widely for risk stratification before invasive procedures in the general surgical population and it has been studied as a predictive factor in case series of patients with cirrhosis.
MELD Score
Initially developed to predict mortality after placement of a transjugular intrahepatic portosystemic shunt (TIPS), 15 the MELD score was later introduced as a means of prioritizing organ allocation for liver transplantation. The MELD score is calculated using the international normalized ratio (INR), serum bilirubin level, and serum creatinine level. Patients with a preoperative MELD score <16 have lower postoperative mortality rates than those with higher scores. 16 One study demonstrated a linear increase in postoperative mortality with an increase in MELD score. This large, singlecenter, retrospective study of patients with cirrhosis who underwent cardiovascular, orthopedic, or major abdominal surgery showed the mortality rate increased steadily up to 90 days following major surgery with increasing MELD scores. 8 A higher ASA class and age >70 years were also predictive of mortality. It is important to emphasize that the patients in this study were carefully selected for surgery after exclusion of significant comorbidity. Mortality could be predicted at 7 days, 30 days, 90 days, and 1 year, and in the long term, with a combination of the MELD score, ASA class, and age. Using these data, the postoperative mortality risk in patients with cirrhosis can be determined through the use of an online calculator (Mayo Postoperative Surgical Risk Score; https://www.mayoclinic.org/medicalprofessionals/model-end-stage-liver-disease/postoperativemortality-risk-patients-cirrhosis). One advantage of this calculator over the MELD score alone is that it includes age and ASA class, which give the model more granularity and greater predictive value. The MELD-Na score has not been studied as a predictor of surgical outcomes in patients with cirrhosis.
Risks of Specific Surgical Procedures in Patients With Cirrhosis
Many case series in the literature, some with historical controls, address the characteristics of various surgical procedures and associated mortality in patients with cirrhosis. Among the different types of surgery, hepatobiliary surgery is perceived to have the highest risk of liver-related mortality and morbidity. Abdominal surgery and possibly thoracic surgery in the presence of portal hypertension are significant risks as well. Whether violation of the abdominal or thoracic cavity is a specific risk factor in and of itself or whether these procedures increase surgical risk because they are more invasive and disruptive of the splanchnic vasculature and collaterals is unknown. Therefore, patients undergoing evaluation for surgery in the presence of cirrhosis require careful selection and extensive discussion involving both the patient and family before the procedure. The urgency of the procedure, although not often a controllable variable, is an important predictor of outcomes. In the general population, emergency surgery for any indication carries a significantly higher risk for morbidity and mortality than nonemergent procedures. 17 This trend has been shown in small series of patients with cirrhosis as well. 18, 19 Based on these small and retrospective studies, patients who undergo an emergency procedure should expect at least a 2-fold increased relative risk of morbidity and mortality that will not be directly represented by MELD-based predictive models (although some models do incorporate emergency surgery as a risk factor). 20 Improvements in surgical technique and medical management have had a positive effect on surgical mortality and morbidity rates. For example, a case series of patients with cirrhosis undergoing nonshunt celiotomy published in 1984 showed a 30% mortality rate, which correlated with the Child-Pugh class. 21 By comparison, a series published in 2010 from a center with extensive experience in surgery in patients with cirrhosis reported a 7% mortality rate for abdominal procedures that was not well predicted by the CTP score but did correlate with the MELD score and serum albumin level. 11 The authors of the latter study suggested that use of a laparoscopic approach was associated with a decreased rate of postoperative complications but acknowledged possible selection bias. There is also an unquantifiable but significant contribution of case experience and multidisciplinary management in the improved surgical outcomes in patients with cirrhosis over the past decades. Several case series have suggested that, compared with more invasive approaches, laparoscopic and other minimally invasive surgical techniques may lead to favorable outcomes in patients with cirrhosis. [22] [23] [24] [25] [26] The lack of concurrent risk-adjusted controls and the small size of most reports make definitive, evidence-based recommendations speculative at best. Similarly, aside from strict avoidance of outdated traditionally hepatotoxic inhalational anesthetic agents, no studies have compared anesthesia techniques in patients with cirrhosis, so decisions regarding the choice of an anesthetic agent must be made on a case-by-case basis. As an example, spinal and epidural anesthesia are known to reduce hepatic blood flow but there are no specific studies addressing anesthesia risk comparing spinal anesthesia to other modalities in cirrhosis patients.
Primary Hepatic Resection
Hepatic resection for HCC is typically considered only in patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 (early) HCC. 27 Stage 0 is defined as a tumor <2 cm in diameter, excellent patient performance status, and normal liver function (Child-Pugh class A) without portal hypertension. A surrogate marker for the lack of portal hypertension in this population is a peripheral platelet count >100,000/mL. Other studies have identified the absence of clinically significant portal hypertension by an hepatic venous pressure gradient (HVPG) <10 mm Hg 28 or the absence of venous collaterals on cross-sectional abdominal imaging along with the absence of esophageal varices on upper endoscopy. The use of liver stiffness measurement (eg, by transient elastography) to guide decisions regarding hepatic surgical resection has been suggested but optimal cutoff values have not been validated. In one series, a liver stiffness measurement below 22 kPa was established as the optimal cutoff level for selecting patients for surgery. 29 A liver stiffness measurement of !22 kPa had greater sensitivity and higher negative as well as positive predictive value in predicting patients likely to experience postoperative hepatic decompensation compared with an HVPG >10 mm Hg. Much lower cutoff values, ranging from 12 to 15 kPa, have also been proposed. 30 A MELD score <9 may also be used to select patients for hepatic resection, because such patients have an excellent prognosis following resection. 31 
Cholecystectomy
Routine abdominal imaging (ultrasonography and other cross-sectional modalities) may show a thickened gallbladder wall in patients with cirrhosis, particularly in patients with ascites. The finding typically reflects fibrotic thickening associated with cirrhosis rather than the edema seen in acute cholecystitis. In fact, in a cirrhotic patient with acute abdominal pain, a misdiagnosis of acute cholecystitis is not uncommon. In general, elective cholecystectomy should be delayed in patients with cirrhosis who are candidates for a liver transplantation. If urgent surgery must be carried out and the diagnosis of acute cholecystitis is certain, patients should be referred urgently to a center with experience in carrying out cholecystectomy in patients with cirrhosis; however, we do not recommend cholecystectomy in patients with Child-Pugh class C cirrhosis or refractory ascites. Such patients are also generally not candidates for percutaneous cholecystostomy, unless they are critically ill, due to the presence of ascites and a high risk of infections and procedural complications. In noncritically ill patients, endoscopic transpapillary gallbladder drainage may be carried out if technically feasible to relieve symptoms, but expertise in the technique is required. 32 Laparoscopic cholecystectomy has been associated with a higher mortality rate in patients with cirrhosis compared with noncirrhotic patients in a populationbased study in the United States. 24 There is also an increased requirement for conversion of laparoscopic cholecystectomy to open cholecystectomy in patients with cirrhosis. In the setting of laparoscopic cholecystectomy, the MELD score correlates well with mortality risk but not with the risk of complications from the surgical procedure itself. 33 Laparoscopic cholecystectomy has not been compared with open cholecystectomy in a prospective study, but in a single retrospective study using historical controls, the laparoscopic approach appeared to be preferable when technically feasible. 34 
Abdominal Wall Hernia Repair
Patients with cirrhosis are prone to abdominal hernias because of the presence of ascites and, to a lesser extent, abdominal organomegaly. Symptomatic hernias are common, especially in the setting of significant ascites, and control of ascites is key to successful hernia repair. Because the ascites inevitably recurs quickly, a single large-volume paracentesis before a surgical procedure does not provide adequate preoperative control of ascites. Medical control of clinically apparent ascites with diuretics, as per practice guidelines, before a surgical hernia repair is required in a patient with decompensated cirrhosis to prevent recurrent ascites postoperatively. Selected surgical candidates may benefit from preemptive placement of a TIPS to control ascites before surgery. Recurrent ascites leads to impaired wound healing and risks possible dehiscence. For this reason, efforts should be undertaken to avoid recurrent ascites in the postoperative period and may include frequent postoperative paracentesis and careful diuretic therapy while attempting to avoid renal injury. In selected patients transient pigtail catheter drainage of ascites postoperatively may prevent pressure on the hernia repair.
Several studies have examined risk factors for mortality after hernia surgery, but most relevant studies are uncontrolled and include a heterogeneous population (for example, elective and emergency cases). Both the MELD score 12 and the Child-Pugh class combined with the ASA class 14 have been advocated for hernia surgery risk stratification, but neither appears to be optimal in all cases.
The emergent presentation of an incarcerated hernia is a special challenge in a patient with cirrhosis and is the most common indication for emergency surgery in this population and a major risk factor for poor outcomes. [17] [18] [19] Because of the significant increase in mortality and morbidity associated with emergency operations in patients with cirrhosis, some authors have advocated elective hernia repair in patients with cirrhosis to prevent an emergent presentation. A singlecenter prospective case series without controls reported on patients listed for liver transplantation who presented for elective umbilical hernia repair. 25 Thirty patients eventually underwent elective surgery, and most had Child-Pugh class B or C cirrhosis, with a median MELD score of 12. Two patients had prolonged hospital stays due to complications, but the remainder did not experience a direct surgical complication. The authors concluded that elective umbilical hernia repair is preferable to emergency repair in patients with cirrhosis and ascites. The lack of controls in this series makes broad conclusions difficult and the frequency of emergency incarceration in patients with cirrhosis with a stable abdominal hernia is unknown. Surgical and medical teams should determine the safety and riskbenefit ratio of elective hernia surgery carefully in this population.
Cardiovascular Surgery
The need for cardiovascular surgery is increasing in patients with cirrhosis as NASH, usually accompanied by components of the metabolic syndrome (which are also risk factors for cardiovascular disease), has become a leading cause of cirrhosis in the developed world. 35 Cardiovascular surgery, especially for an urgent indication, can be life-extending, even in patients with significant complications from cirrhosis. Cardiovascular operations, especially those requiring cardiac bypass and extracorporeal circulation, pose unique physiologic challenges for the patient, including hyperfibrinolysis, platelet activation, and the need for anticoagulation during and frequently after the procedure. Nevertheless, studies are limited with regard to the optimal management of patients with cirrhosis and these intraoperative and postoperative issues. 36, 37 Case series and cohort studies using historical controls show relatively high morbidity and mortality rates in patients with cirrhosis who undergo cardiac surgery. 35, 38, 39 Most cardiac surgery teams use viscoelastic testing such as thromboelastography or rotational thromboelastometry 40 in the management of patients undergoing these operations, an approach that seems clinically reasonable because the technology has been tested extensively in persons with cirrhosis. 41 Several prospective and retrospective case series without controls and with historical controls have evaluated the value of the MELD and CTP scores in predicting outcomes after cardiac surgery, but the data are limited by small numbers of patients, inclusion of only patients cleared for surgery, and a vast preponderance of patients with compensated cirrhosis with a low MELD score. [42] [43] [44] [45] [46] [47] Overall, elective coronary artery bypass graft surgery is associated with mortality rates ranging from 4% to 70%, which correlate with the MELD score and the Child-Pugh class. In general, a MELD score !13.5 46 or a CTP score >7 47 is considered a contraindication to cardiac surgery. No specific studies have compared the various surgical approaches. A small study of patients undergoing aortic valve replacement 48 showed no significant difference in mortality between transcatheter aortic valve replacement and surgical aortic valve replacement. Coronary angiography and cardiac catheterization are performed routinely in patients with cirrhosis undergoing liver transplant evaluation and appear to be relatively safe in this population. Based on a single uncontrolled case series, transfusion of plasma to prophylactically "correct" the INR before the procedure cannot be recommended. 49 There are sparse data on the use of antiplatelet agents after coronary stent placement and after cardiac surgery in patients with cirrhosis, but available studies suggest an increase in the risk of variceal and nonvariceal bleeding when these patients receive dual antiplatelet therapy.
50,51

Bariatric Surgery
Obesity is the most common risk factor for cirrhosis in developed countries, and NASH cirrhosis is among the most common indications for listing patients for liver transplantation. Weight loss through lifestyle changes benefit patients with obesity and NASH but is difficult to achieve. 52 Bariatric surgery may be carried out at expert centers in patients with compensated cirrhosis but without clinically significant portal hypertension. Even in skilled hands, the risk of complications is increased compared with that in the general population, [53] [54] [55] [56] although studies regarding risk stratification of cirrhotic patients before surgery are lacking. However, patients with decompensated cirrhosis or with clinically significant portal hypertension are at highest risk for adverse outcomes and are not candidates for bariatric procedures. Several centers have reported the outcomes of sleeve gastrectomy preformed at the time of liver transplantation. Such a combined procedure in highly selected patients is associated with durable weight loss and a lower risk of the metabolic syndrome 57,58 after liver transplantation. A sleeve gastrectomy, which involves resection of the greater curvature of the stomach, does not add significant morbidity to the liver transplant procedure and is not associated with intestinal malabsorption postoperatively, which is a particular concern in the prevention of perioperative graft rejection that could result from malabsorption of immunosuppression medications. Weight loss following the procedure is gradual, and endoscopic access to the biliary tract is preserved should the patient develop posttransplant biliary complications. A few centers have reported case series of Roux-en-Y gastric bypass 59 and sleeve gastrectomy after liver transplantation, 60 but because of small numbers of patients, we cannot make conclusions about safety and efficacy. Table 3 lists risk stratification tools used for various surgical procedures in the setting of cirrhosis. The data are derived primarily from small case series, and limited conclusions can be made on the accuracy of the predictive models for many of the operations.
Other Surgical Procedures
Preoperative and Perioperative Evaluation and Management of the Patient With Cirrhosis
Surgical procedures that are generally considered safe in the medical population without significant comorbidities may pose great risk in the patient with decompensated cirrhosis. Early involvement of an experienced multidisciplinary medical and surgical team is an absolute key to success. Earnest and data-driven risk discussions with both the patient and the surgical teams are a critical prerequisite for an informed decision about surgical procedures in this population, and the discussion should begin as early in the process as possible. For patients undergoing elective or semielective procedures, ascites should be controlled, variceal bleeding risk reduced, and acute hepatic encephalopathy treated preoperatively, with continuation of medical therapy to prevent recurrent hepatic encephalopathy. With the aging of the population and the increasing prevalence of obesity, NASH, and diabetes mellitus, the patient with cirrhosis is likely to have nonhepatic risk factors for surgical complications as well. No specific studies have examined whether nonhepatic comorbid risk factors such as cardiopulmonary disease are additive or multiplicative to the risk imparted by liver disease. Clinical experience suggests, however, that class III obesity and cardiopulmonary disease are risk factors for morbidity and mortality independent of the severity of liver disease. Similarly, most of the major risk stratification scores do not include age, but the extremes of age are known to be independent risk factors for medical and surgical complications. In fact, both the CTP and MELD scores are predictive of surgical outcome only in patients who are otherwise satisfactory candidates for surgery and have no other important comorbidities. Therefore, cardiology and pulmonology consultations are frequently needed for these complex patients.
Elective operations in patients with cirrhosis should generally be avoided until the liver disease can be optimized. Progressive decompensation is well described in the postoperative period in patients with previously fully compensated cirrhosis. For chronic viral hepatitis and autoimmune hepatitis, strict adherence to antiviral and immunosuppressive therapy is required to avoid viral resistance and relapse, respectively, and elective or semielective surgery may be delayed until therapy is completed to avoid an interruption in treatment. Alternative routes of drug administration may be necessary such as the use of intravenous administration of corticosteroids in patients with autoimmune hepatitis who are unable to take oral medications.
Ascites
Ascites should be managed aggressively, as recommended by practice guidelines, 61 before surgical procedures, if possible. Ascites can restrict pulmonary function and delay perioperative recovery of lung function. Patients with ascites are also at risk of pulmonary aspiration during induction of anesthesia. Therefore, in patients with symptomatic ascites, large-volume total abdominal paracentesis should be performed preoperatively, with intravenous administrative of albumin in a dose of 6-8 g for each liter of ascitic fluid removed. Once oral medications are tolerated, daily antibiotic prophylaxis can be resumed in patients with a history of spontaneous bacterial peritonitis and patients with a low ascitic total protein concentration, as per practice guidelines. In patients who are not able to take oral medications, third-generation cephalosporins such as ceftriaxone, can be administered prophylactically in a dose of 1 g every 24 hours intravenously until oral intake of prophylactic antibiotics is possible again. Preoperative thoracentesis is only recommended in patients with moderate to large pleural effusions that compromise respiratory function. Administration of intravenous fluid and blood products should be limited perioperatively to avoid increasing extracellular volume, ascites, and portal venous pressure. 62 Only a few case reports and uncontrolled case series have assessed the benefit of preemptive TIPS placement before surgery to reduce the risk of collateral vessel and intra-abdominal variceal bleeding intraoperatively. [63] [64] [65] Although a decrease in the need for intraoperative blood transfusions following TIPS placement is claimed, the available studies have been uncontrolled and the frequency of complications, such as hepatic encephalopathy, following TIPS placement is not reported. In contrast, a retrospective study of liver transplantation performed in patients who had undergone placement of a TIPS before transplantation compared with concurrent controls who had not undergone preoperative TIPS placement showed no difference in red blood cell or plasma transfusion requirements between the 2 groups. 66 Moreover, in a patient undergoing nontransplant surgery, a TIPS that is misplaced into the right atrium, inferior vena cava, or mesenteric veins may adversely affect future liver transplantation. 67 Therefore, owing to unproven efficacy, lack of published evidence, potentially high complication rates, and significant added expense, preemptive TIPS placement before a surgical procedure cannot be recommended as a routine practice.
Hemostasis and Coagulation
Protocol transfusion strategies based on preoperative platelet counts and the INR are generally ineffective in reducing intra-and postoperative bleeding. Patients with cirrhosis are known to be in a state of "rebalance" in that deficits in procoagulant factors are offset by deficits in anticoagulant proteins synthesized by the liver. 4 Therefore, they are not necessarily predisposed to severe bleeding. 68 In fact, as liver disease advances, progressive protein C deficiency leads to a thrombophilic state in some patients. 69 These observations argue strongly against preoperative protocol transfusions in most patients with cirrhosis. The INR is not predictive of bleeding complications in patients with cirrhosis, and "prophylactic" preoperative fresh frozen plasma transfusions are not recommended. 70 Although thrombocytopenia is common in patients with cirrhosis, in vitro 71 and retrospective cross-sectional studies 72 have shown that platelet counts above 50,000/mL are adequate to allow clot formation in most patients with cirrhosis. Prophylactic transfusions to raise the platelet count to higher levels are unlikely to be beneficial and may expose the patient to complications of transfusions, volume overload, or unexpected thrombosis. In recent years, thrombopoietin analogues (romiplostim) and receptor agonists (eltrombopag, avatrombopag, and lusutrombopag) have been developed for the treatment of thrombocytopenia due to idiopathic thrombocytopenic purpura. Eltrombopag is also labeled for use in patients with cirrhosis due to chronic hepatitis C to allow increasing platelet counts during antiviral therapy with interferon. 73 Only avatrombopag and lusutrombopag are approved for the general thrombocytopenia related to liver disease. In patients with cirrhosis, avatrombopag and lusutrombopag were effective in raising platelet counts above 50,000/mL in phase 3 clinical trials when given before invasive procedures compared with placebo. 74, 75 Notably, the rates of bleeding events in both pivotal studies were equivalent in the study drug and placebo arms, thus raising questions about the need for elevating the platelet count before most invasive procedures. Moreover, thrombotic events have occurred with the use of these agents in patients with liver disease and the drugs should be used with caution. At this time, there is no clear guidance in the literature on when to use these agents preoperatively in patients with cirrhosis, but it would seem reasonable to consider their use in patients undergoing an elective procedure associated with a high bleeding risk if the baseline platelet count is less than 50,000/mL. Special attention should be paid to the potential for thrombotic events such as portal vein thrombosis and other deep vein thromboses. Further clinical studies with these agents are ongoing.
Low fibrinogen levels are associated with an increased bleeding risk, 76 and levels <100 mg/dL are associated with a risk of inhibiting clot formation in patients with cirrhosis. Fibrinogen can be replaced with low-volume cryoprecipitate transfusions, which do not significantly increase plasma volume. Although no controlled trials of the efficacy of fibrinogen transfusion in patients with cirrhosis have been undertaken, it seems physiologically reasonable to replete fibrinogen levels with infusions of cryoprecipitate before high-risk surgical procedures to allow the substrate for adequate clot formation.
Viscoelastic testing (thromboelastography and rotational thromboelastometry) to guide intraoperative transfusions is available at large centers and has been shown to decrease the need for red blood cell and plasma transfusions in the general surgical population 77 and specifically in patients with cirrhosis. 78 If available, viscoelastic testing should be considered before and during surgical procedures in patients with cirrhosis to help guide a rational transfusion strategy. Details about these testing modalities are available elsewhere. 40 
Pain Control
Because of altered drug metabolism and elimination, patients with cirrhosis are at especially high risk of medication-related toxicity. Opiates should generally be used at lower than standard doses and at longer dosing intervals than in the general population. Although randomized controlled trials have not been performed in patients with cirrhosis, hydromorphone and transdermal fentanyl may be the preferred agents. 79 Protein binding and hepatic metabolism are the primary determinants of benzodiazepine elimination, and only short-acting benzodiazepines such as midazolam should be used. Tramadol, which has favorable hepatic metabolism, 80 or acetaminophen, 81 in a dose of no more than 2 g daily, is also recommended despite the misconception that acetaminophen, even in small doses, is contraindicated in patients with cirrhosis. On the other hand, avoid routine use of nonsteroidal anti-inflammatory drugs (NSAIDs), which can impair renal blood flow in patients with cirrhosis. 82 Similarly, oral combination products containing either acetaminophen or NSAIDs, especially when combined with an opioid, should not be used and can lead to accidental toxicity or overdose in a patient who is unaware that acetaminophen is a component of the product.
Avoid constipation in patients with cirrhosis to minimize flares of hepatic encephalopathy in the postoperative period. Polyethylene glycol solution may be used daily to maintain bowel regularity. In the absence of comparative trials, rifaximin may be preferable in patients with hepatic encephalopathy who undergo primary bowel surgery, because it generally causes less bowel distension than lactulose.
Rescue Liver Transplantation
Before a surgical procedure, it is important to determine whether or not the patient will be a candidate for liver transplantation in the future. In patients who, for whatever reason, are not potential candidates for liver transplantation, it is vital that this position be made clear before proceeding with surgery to avoid the need for the patient's family and the medical team to readdress this issue if the patient's condition deteriorates postoperatively. If the patient is a candidate for liver transplantation, a decision should be made as to whether the planned surgery can be postponed until the patient has undergone liver transplantation. Elective operations such as orthopedic procedures may be best deferred despite uncertainty as to the length of time the patient will be on the liver transplant waiting list. When a procedure cannot be delayed because of the adverse impact on the patient's quality of life, the liver transplant evaluation should be completed before the anticipated surgery, if possible. Making a decision regarding liver transplant candidacy is not easy and depends in part on how quickly the liver transplant evaluation can be completed if the patient deteriorates following surgery and how likely the patient will be to undergo transplantation in the near future. In general, if the postoperative mortality risk is calculated to be >15% at 3 months (using an appropriate risk calculator, as described previously) or if the MELD score is >15 (a score predictive of increased mortality), 16 preoperative evaluation for liver transplantation is recommended.
Conclusions
Invasive surgery is frequently required in the patient with cirrhosis and perioperative management is challenging. Although morbidity and mortality rates correlate with progression of portal hypertension in this population, the MELD score and, to a lesser extent, CTP score (and Child-Pugh class) can provide some prediction of risk in counseling patients and their families. A multidisciplinary approach to these patients is critical for optimizing all phases of perioperative care, including planning, preoperative evaluation, intraoperative management, and postoperative recovery. The data in the literature are limited in scope, usually lack risk-matched controls, and are based largely on single-center experiences; therefore, evidence-based recommendations are mostly lacking. Studies of larger cohorts with matched controls and randomized controlled trials are needed to improve our understanding and management of this challenging population.
